<DOC>
	<DOCNO>NCT02169492</DOCNO>
	<brief_summary>The main objective study assess safety effectiveness ReVive SE ( Self- Expanding ) Neurothrombectomy Device subject require mechanical thrombectomy use accord Instruction use ( IFU ) .</brief_summary>
	<brief_title>Evaluation ReVive SE Device Intra-Arterial Thrombectomy Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<criteria>1 . Age ≥ 18 year old 2 . Clinical sign consistent acute ischemic stroke 3 . No prestroke functional dependence ( prestroke Modified Rankin Score ≤ 1 ) 4 . NIHSS ≥ 6 , , assess within two hour treatment ReVive SE 5 . Large ( ≥ 1.5mm ) proximal vessel occlusion ( present TICI score 0 1 ) MCA ( M1M2 ) , dICA , BA confirm CT/MR angiography accessible ReVive SE . 6 . Treatment initiate within 8 hour symptom onset ( first ReVive SE pas make within 6 hour 7 . Subject legally authorize representative provide informed consent data collection , consent document 1 . Life expectancy le 90 day 2 . Neurological sign rapidly improve prior time treatment ( NIHSS improve least 4 point subject presentation treatment initiation ) 3 . Subject either exhibit clinical sign suggestive , angiographic evidence bilateral stroke 4 . Prior use mechanical device treat stroke ( e.g. , Merci Retriever , Penumbra , Solitaire , Trevo , Mindframe , Phenox , stent ) 5 . Known bleed diathesis : 1 . Current use oral anticoagulant ( eg , warfarin sodium ) International Normalized Ratio ( INR ) &gt; 3 ; 2 . Administration heparin Novel Oral AntiCoagulants ( NOAC , eg Dabigatran , Rivaroxaban ) within 48 hour precede onset stroke abnormal activate partial thromboplastin time ( aPTT ) presentation ; and/or 3 . Platelet count &lt; 100,000/mm3 6 . Glucose &lt; 50 mg/dL ( 2.8 mmol , 2.6mM ) 7 . Uncontrolled hypertension ( SBP &gt; 185 DBP &gt; 110 ) refractory pharmacological management 8 . Known hypersensitivity allergy nitinol and/or radiographic contrast agent 9 . Pregnancy lactate female 10 . Subject already enrol clinical study involve experimental medication device Imaging Exclusion criterion : 11 . CT scan MRI evidence acute intracranial hemorrhage , mass effect and/or intracranial tumor . 12 . Angiographic evidence carotid dissection , high grade stenosis ( &gt; 50 % stenosis artery proximal target vessel ) prevent access clot , cerebral vasculitis 13 . Blood vessel extreme tortuosity condition prevent access device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Thrombectomy</keyword>
	<keyword>Stroke</keyword>
	<keyword>ReVive SE</keyword>
</DOC>